Cancer

Treating metastatic prostate cancer

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.

Vanderbilt-Ingram Cancer Center calls for action to get cancer-preventing HPV vaccination back on track

A significant reduction in annual well visits and immunizations during the COVID-19 pandemic has led to a vaccination gap among U.S. children and adolescents, especially with the human papillomavirus (HPV) vaccine for cancer prevention.

Vanderbilt researchers present new data on clinical trials at ASCO 2021

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

Analysis reveals macrophages associated with kidney cancer recurrence

A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.

People at high genetic risk for colorectal cancer benefit more from lifestyle changes

People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.

The Vanderbilt Ingram Cancer Center (Neil Brake/Vanderbilt)

AACR second session to feature Vanderbilt researchers

The second session of the American Association for Cancer Research (AACR) Annual meeting, May 17-21, features several researchers from Vanderbilt-Ingram Cancer Center.

1 19 20 21 22 23 68